CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CX-2029’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - CX-2029 in Prostate Cancer

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CX-2029 overview

CX-2029 was under development for the treatment of solid tumors including squamous non-small cell lung cancer (sqNSCLC), squamous head and neck cancer (sqHNSCC), esophageal cancer, gastroesophageal (GE) junction cancers,
lymphomas including diffuse large B-cell lymphoma, adenoid cystic carcinoma of parotid gland, colorectal cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, malignant pleural mesothelioma, non-small cell lung carcinoma, non-small cell lung carcinoma, ovarian cancer, oncocytic carcinoma of parotid gland, ocular melanoma pancreatic cancer, prostate cancer, perivascular epithelioid cell tumor, soft tissue sarcoma, bladder cancer, thyroid carcinoma, thymoma or thymic cancers, renal cell cancer and hepatocellular cancer. It is administered intravenously. The drug candidate is developed based on probody platform. The drug candidate acts by targeting CD71 (transferrin receptor) an tubulin inhibitor, monomethyl auristatin E (“MMAE”) as the payload. It was also under development for the treatment breast cancer. It was also under development for Burkitt lymphoma.

CytomX Therapeutics overview

CytomX Therapeutics (Cytomx) is a clinical-stage biopharmaceutical company. it develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company product pipeline include CX-2029, CX-904 and BMS-986288. Its pipeline carries out SqNSCLC, esophageal/GEJ and solid tumors. Cytomx also provides probody therapeutics for the treatment of cancer. It has collaborated with Abbvie, Amgen, Astellas, Regeneron and Moderna among others. The company also carries out various phases of clinical trails. Cytomx is headquartered in South San Francisco, California, the US.

For a complete picture of CX-2029’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.